Pfizer Inc. (0Q1N.L)
| Previous close | 50.58 |
| Open | 50.82 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 50.26 - 50.82 |
| 52-week range | 33.27 - 54.90 |
| Volume | |
| Avg. volume | 236,987 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
Pfizer unveils positive phase 3 trial results for RSV vaccine
Pfizer (PFE) has released the results from its Phase 3 clinical trial for its RSV vaccine. The trial showed positive outcomes for adults aged 18-59, widening the population that can potentially benefit from the vaccine. Previously, Pfizer's RSV vaccine had been approved for use in pregnant women and adults aged 60 and older. Yahoo Finance's Health Reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. Editor's note: This article was written by Angel Smith
- Bloomberg
China Loosens Cross-Border Data Rules on Business Pressure
(Bloomberg) -- China relaxed rules governing cross-border data flows, addressing a key concern of foreign businesses that had complained previous regulations were disrupting their operations.Most Read from BloombergLondon Insurers Face Baltimore Bridge Payouts Worth BillionsBiden Gains Ground Against Trump in Six Key States, Poll ShowsJapan Amps Up Intervention Threat as Yen Hits Lowest Since 1990China Property Crisis Is Rippling Through Its Biggest BanksTrump’s Net Worth Hits $6.5 Billion, Maki
- Yahoo Finance
Moderna CEO: 2024 is year of growth, with 2023 transition in rearview
Moderna posted strong results despite investors assuming a loss for the year.
